Literature DB >> 31520312

A Novel Adverse Event of Nusinersen Treatment: Thrombocytosis.

Nagehan Aslan1, Dincer Yildizdas2, Yasemin Coban2, Ozden Ozgur Horoz2, Gulen Gul Mert3, Neslihan Ozcan3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31520312     DOI： 10.1007/s12098-019-03069-1

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN： 0019-5456            Impact factor:   1.967


× No keyword cloud information.
  4 in total

1.  Extreme thrombocytosis under the treatment by amoxicillin/clavulanate.

Authors:  Chih-Jen Yang; Jhi-Jhu Hwang; Jen-Yu Hung; Inn-Wen Chong; Ming-Shyan Huang
Journal:  Pharm World Sci       Date:  2006-11-17

Review 2.  Nusinersen in the Treatment of Spinal Muscular Atrophy.

Authors:  Kara Goodkey; Tejal Aslesh; Rika Maruyama; Toshifumi Yokota
Journal:  Methods Mol Biol       Date:  2018

Review 3.  Nusinersen: First Global Approval.

Authors:  Sheridan M Hoy
Journal:  Drugs       Date:  2017-03       Impact factor: 9.546

Review 4.  Nusinersen for the treatment of spinal muscular atrophy.

Authors:  Claudia A Chiriboga
Journal:  Expert Rev Neurother       Date:  2017-09-08       Impact factor: 4.618
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.